155 related articles for article (PubMed ID: 10505957)
21. Pharmacokinetics and pharmacodynamics of phenylbutazone and oxyphenbutazone in the donkey.
Cheng Z; McKellar QA; Nolan A; Lees P
J Vet Pharmacol Ther; 1996 Apr; 19(2):149-51. PubMed ID: 8735424
[No Abstract] [Full Text] [Related]
22. Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses.
Knych HK; Arthur RM; McKemie DS; Seminoff K; Hamamoto-Hardman B; Kass PH
Drug Test Anal; 2019 Jun; 11(6):792-803. PubMed ID: 30499176
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of phenylbutazone in neonatal foals.
Wilcke JR; Crisman MV; Sams RA; Gerken DF
Am J Vet Res; 1993 Dec; 54(12):2064-7. PubMed ID: 8116939
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of methocarbamol and phenylbutazone in exercised Thoroughbred horses.
Knych HK; Stanley SD; Seminoff KN; McKemie DS; Kass PH
J Vet Pharmacol Ther; 2016 Oct; 39(5):469-77. PubMed ID: 26924025
[TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacokinetics of phenylbutazone in healthy young-adult and geriatric horses.
Zaghloul IY; Bedenice D; Ceresia ML; Jones PH; Sanchez-Londono A; Lobo MN; Böhlke M; Paradis MR
Am J Vet Res; 2024 Jun; ():1-8. PubMed ID: 38942059
[TBL] [Abstract][Full Text] [Related]
26. [The concentration changes of different phenylbutazone formulations in horse plasma].
Keller H; Hashem A
Dtsch Tierarztl Wochenschr; 1996 Jun; 103(6):224-30. PubMed ID: 8766906
[TBL] [Abstract][Full Text] [Related]
27. Effects of single-dose intravenous phenylbutazone on experimentally induced, reversible lameness in the horse.
Foreman JH; Barange A; Lawrence LM; Hungerford LL
J Vet Pharmacol Ther; 2008 Feb; 31(1):39-44. PubMed ID: 18177317
[TBL] [Abstract][Full Text] [Related]
28. Analysis of phenylbutazone residues in horse tissues with and without enzyme-hydrolysis by LC-MS/MS.
Boison JO; Dowling T; Johnson R; Kinar J
Drug Test Anal; 2016 May; 8(5-6):535-8. PubMed ID: 27443208
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.
Knych HK; Arthur RM; McKemie DS; Baden RW; Seminoff K; Kass PH
Equine Vet J; 2021 Jan; 53(1):102-116. PubMed ID: 32145701
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid - a comparison with ketoprofen.
Armstrong S; Tricklebank P; Lake A; Frean S; Lees P
J Vet Pharmacol Ther; 1999 Jun; 22(3):196-201. PubMed ID: 10447830
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and synovial fluid concentrations of flurbiprofen enantiomers in horses: chiral inversion.
Soraci AL; Tapia O; Garcia J
J Vet Pharmacol Ther; 2005 Feb; 28(1):65-70. PubMed ID: 15720517
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans.
Yasuda Y; Shindo T; Mitani N; Ishida N; Oono F; Kageyama T
J Pharm Sci; 1982 May; 71(5):565-72. PubMed ID: 7097505
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals.
Ferre PJ; Laroute V; Braun JP; Cazaux J; Toutain PL; Lefebvre HP
J Anim Sci; 2006 May; 84(5):1295-301. PubMed ID: 16612034
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of phenylbutazone in llamas following single intravenous and oral doses.
Navarre CB; Ravis WR; Nagilla R; Simpkins A; Duran SH; Pugh DG
J Vet Pharmacol Ther; 2001 Jun; 24(3):227-31. PubMed ID: 11442803
[No Abstract] [Full Text] [Related]
35. Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses.
Gerken DF; Sams RA
J Pharmacokinet Biopharm; 1985 Oct; 13(5):467-76. PubMed ID: 3834064
[TBL] [Abstract][Full Text] [Related]
36. Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses.
Foreman JH; Ruemmler R
Equine Vet J Suppl; 2011 Nov; (40):12-7. PubMed ID: 22082440
[TBL] [Abstract][Full Text] [Related]
37. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses.
Toutain PL; Lassourd V; Costes G; Alvinerie M; Bret L; Lefebvre HP; Braun JP
J Vet Pharmacol Ther; 1995 Jun; 18(3):226-35. PubMed ID: 7674460
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of phenylbutazone and its metabolites in the horse.
Gerring EL; Lees P; Taylor JB
Equine Vet J; 1981 Jul; 13(3):152-7. PubMed ID: 7297544
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous high-performance liquid chromatographic determination of suxibuzone and its metabolites in plasma and urine.
Marunaka T; Shibata T; Minami Y; Umeno Y; Shindo T
J Pharm Sci; 1980 Nov; 69(11):1258-61. PubMed ID: 7452452
[TBL] [Abstract][Full Text] [Related]
40. Phenylbutazone kinetics and metabolite concentrations in the horse after five days of administration.
Soma LR; Gallis DE; Davis WL; Cochran TA; Woodward CB
Am J Vet Res; 1983 Nov; 44(11):2104-9. PubMed ID: 6650958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
